{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.389","value":"-7.88"},{"groupId":"OG001","spread":"13.520","value":"-4.85"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.631","value":"-14.77"},{"groupId":"OG001","spread":"26.318","value":"-12.12"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.440","value":"-6.06"},{"groupId":"OG001","spread":"22.218","value":"1.52"}]}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.872","value":"-8.71"},{"groupId":"OG001","spread":"19.009","value":"-6.82"}]}],"title":"Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.000","value":"-10.98"},{"groupId":"OG001","spread":"21.656","value":"-7.58"}]}],"title":"Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.367","value":"11.87"},{"groupId":"OG001","spread":"18.444","value":"8.59"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.025","value":"-1.89"},{"groupId":"OG001","spread":"24.922","value":"-0.76"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.128","value":"9.85"},{"groupId":"OG001","spread":"12.037","value":"-0.76"}]}],"title":"Nausea/Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.529","value":"-7.77"},{"groupId":"OG001","spread":"22.150","value":"-10.61"}]}],"title":"Global Health Status/QoL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.041","value":"6.06"},{"groupId":"OG001","spread":"21.767","value":"1.52"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.682","value":"12.88"},{"groupId":"OG001","spread":"19.616","value":"6.06"}]}],"title":"Loss of Appetite"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.190","value":"6.06"},{"groupId":"OG001","spread":"24.618","value":"-15.15"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.452","value":"11.36"},{"groupId":"OG001","spread":"12.503","value":"1.52"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.792","value":"6.82"},{"groupId":"OG001","spread":"28.469","value":"13.64"}]}],"title":"Diarrhea"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a 30-item self-administered questionnaire grouped into 5 multi-item functional scales(physical,role,emotional,cognitive and social),3 multiitem symptom scales(fatigue,pain and nausea/vomiting),2-item global QoL scale,5 single items assessing additional symptoms reported by cancer participants(dyspnea,loss of appetite,insomnia,constipation and diarrhea). All but 2 questions have 4-point scales:1:not at all,2:a little,3:quite a bit,4:very much.2 questions concerning global health status and QoL have 7-point scales with responses ranging from 1:very poor to 7:excellent;higher score:better level of functioning/greater degree of symptoms.For each of 15 scales,final scores were averaged from scores of component items,transformed,range: 0 to 100;higher scores:better functioning,better health related (HR)QoL,or greater level of symptoms(higher scores:opposite interpretations for functioning/QoL and symptoms/problems).Baseline:last observed measurement prior to randomization.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized participants. Only participants with data collected in specified categories are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and Week 91","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Score at Week 91","type":"SECONDARY","unitOfMeasure":"score on a scale"}